Proven Weight Loss

Clinical programs with semaglutide show around 10–15% average body-weight reduction at therapeutic dosing.

Cardiometabolic Support

Improves glycemic control and cardiometabolic markers as part of a comprehensive plan.

FDA Approved*

Approved for type 2 diabetes and for chronic weight management at specific doses.

Contraindications & Precautions

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)

• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

• Known hypersensitivity to semaglutide

Use with Caution

• History of pancreatitis

• Gallbladder disease

• Diabetic retinopathy

• Severe gastrointestinal disease

• Renal impairment

• Pregnancy or breastfeeding

Results, Dosing & Side Effects

Weight-Management Outcomes

• Average weight loss ~10–15% with ongoing therapy

• Improvements in waist circumference and body composition

• Enhanced satiety and reduced caloric intake

• Better adherence with weekly dosing

Glycemic Benefits

• Meaningful reductions in HbA1c

• Low hypoglycemia risk when not used with insulin/sulfonylureas

• Supports cardiometabolic health

• Once-weekly injection for convenience

Clinical Trial Highlight

Across pivotal trials for weight management, semaglutide 2.4 mg once weekly produced about a ~15% mean weight reduction over the full treatment period when paired with lifestyle support.

Dosing & Administration (Weight Management)

Route: Subcutaneous injection once weekly

Typical Titration:

• 0.25 mg once weekly × 4 weeks

• 0.5 mg once weekly × 4 weeks

• 1.0 mg once weekly × 4 weeks

• 1.7 mg once weekly × 4 weeks

• 2.4 mg once weekly (maintenance, as tolerated)

Injection Sites: Abdomen, thigh, or upper arm; rotate sites weekly.

Note: Diabetes dosing schedules may differ (e.g., 0.5–2.0 mg weekly based on indication and product).

Side Effects — Common (≥5%)

• Nausea, vomiting, diarrhea

• Constipation, abdominal pain

• Headache, fatigue

• Injection-site reactions

Side Effects — Serious (Rare)

• Pancreatitis

• Gallbladder disease

• Acute kidney injury (typically with dehydration)

• Severe hypoglycemia (when combined with insulin/sulfonylureas)

• Thyroid C-cell tumor risk observed in rodents (boxed warning)

Why Choose Semaglutide?

Semaglutide is a GLP-1 receptor agonist that targets key metabolic pathways—reducing appetite, improving glycemic control, and supporting sustainable weight loss with simple once-weekly dosing.

Patient Story:
“I’ve lost 27 pounds in 16 weeks on semaglutide. Cravings are manageable, my energy is steady, and my blood sugar is finally on track.” — Jasmine K.

Mechanism of Action

• GLP-1 Receptor Activation: Increases glucose-dependent insulin secretion and lowers glucagon.

• Gastric Emptying: Slows gastric emptying to enhance satiety and reduce caloric intake.

• Central Appetite Effects: Acts on brain centers that regulate hunger and fullness.

• Metabolic Support: Improves glycemic control and supports cardiometabolic health.

*Approval details depend on indication, dose, and region. Educational content only—patients should consult a licensed medical professional.